Bal Pharma Stock Price Analysis and Quick Research Report. Is Bal Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Bal Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Bal Pharma has a PE ratio of 22.4870944726571 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Bal Pharma has ROA of 1.8236% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Bal Pharma has a Current ratio of 1.1329.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Bal Pharma has a ROE of 6.6539%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Bal Pharma has a Debt to Equity ratio of 1.4769 which means that the company has low proportion of debt in its capital.

• Sales growth: Bal Pharma has reported revenue growth of 2.744% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Bal Pharma for the current financial year is 10.4370376805439%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Bal Pharma is Rs 1.2 and the yield is 1.1482%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Bal Pharma is Rs 4.7654. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Bal Pharma in Ticker for free. Also, one can get the intrinsic value of Bal Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Bal Pharma FAQs

Q1. What is Bal Pharma share price today?
Ans: The current share price of Bal Pharma is Rs 107.16.

Q2. What is the market capitalisation of Bal Pharma?
Ans: Bal Pharma has a market capitalisation of Rs 170.608064352 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Bal Pharma?
Ans: The PE ratio of Bal Pharma is 22.4870944726571 and the P/B ratio of Bal Pharma is 1.62082693029053, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Bal Pharma share?
Ans: The 52-week high share price of Bal Pharma is Rs 124.6, and the 52-week low share price of Bal Pharma is Rs 60.

Q5. Does Bal Pharma pay dividends?
Ans: Currently, Bal Pharma pays dividends. Dividend yield of Bal Pharma is around 1.1482%.

Q6. What are the face value and book value of Bal Pharma shares?
Ans: The face value of Bal Pharma shares is Rs 10, while the book value per share of Bal Pharma is around Rs 66.1144. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Bal Pharma?
Ans: Bal Pharma has a total debt of Rs 153.7479 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Bal Pharma?
Ans: The ROE of Bal Pharma is 6.6539% and ROCE of Bal Pharma is 9.3288%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Bal Pharma a good buy for the long term?
Ans: The Bal Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Bal Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Bal Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Bal Pharma’s financials?
Ans: You can review Bal Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.